Wechselwirkungen von Docetaxel

The alcohol content in a dose of Docetaxel Injection may affect the central nervous system and should be taken into account for patients in whom alcohol intake should be avoided or minimized. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. (Fachinformation zu Docetaxel, Boxed Warning (umrahmter Warnhinweis))

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients who have previously experienced a hypersensitivity reaction to paclitaxel may develop a hypersensitivity reaction to docetaxel that may include severe or fatal reactions such as anaphylaxis. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

In BCIRG006, a total of 2.9% (31/1056) of patients in the TCH (docetaxel, carboplatin, trastuzumab) arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued trastuzumab due to cardiac toxicity. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

In the 251 patients with metastatic breast cancer who received XELODA with docetaxel, 68% had grade 3 or 4 neutropenia, 2.8% had grade 3 or 4 thrombocytopenia, and 10% had grade 3 or 4 anemia. (Fachinformation zu Capecitabin, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Treatment-related AML or MDS has occurred in patients given anthracyclines and/or cyclophosphamide, including use in adjuvant therapy for breast cancer. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

In the adjuvant breast cancer trial (TAX316) AML occurred in 3 of 744 patients who received docetaxel, doxorubicin, and cyclophosphamide (TAC) and in 1 of 736 patients who received fluorouracil, doxorubicin, and cyclophosphamide [ see Clinical Studies (14.2) ]. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (Fachinformation zu Docetaxel, Arzneimittelwechselwirkungen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)